CA2225666A1 - Utilisation de composes se liant specifiquement au domaine stat 5 sh2 pour augmenter l'erythropoiese - Google Patents

Utilisation de composes se liant specifiquement au domaine stat 5 sh2 pour augmenter l'erythropoiese Download PDF

Info

Publication number
CA2225666A1
CA2225666A1 CA002225666A CA2225666A CA2225666A1 CA 2225666 A1 CA2225666 A1 CA 2225666A1 CA 002225666 A CA002225666 A CA 002225666A CA 2225666 A CA2225666 A CA 2225666A CA 2225666 A1 CA2225666 A1 CA 2225666A1
Authority
CA
Canada
Prior art keywords
domain
binding affinity
binds
stat
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002225666A
Other languages
English (en)
Inventor
Damien John Dunnington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2225666A1 publication Critical patent/CA2225666A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un procédé pour améliorer l'érythropoïèse chez un sujet, consistant à lui administrer une quantité suffisante pour avoir un effet thérapeutique d'un composé qui se fixe au domaine Stat 5 SH2 humain avec une affinité de fixation supérieure par un facteur d'au moins 50 à son affinité de fixation au domaine Stat 6 SH2 humain, qui se fixe au domaine hcp SH2 humain, au domaine Grb2 SH2 humain, au domaine SH-PTP2 SH2 humain et au domaine p85 SH2 humain avec une affinité de fixation inférieure par un facteur d'au moins 50 à son affinité de fixation au domaine Stat 5 SH2, et qui se fixe au domaine src SH2 humain, au domaine lck SH2 humain et au domaine fyn SH2 humain avec une affinité de fixation inférieure par un facteur d'au moins 50 à son affinité de fixation au domaine Stat 5 SH2 humain.
CA002225666A 1995-06-30 1996-06-28 Utilisation de composes se liant specifiquement au domaine stat 5 sh2 pour augmenter l'erythropoiese Abandoned CA2225666A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49735795A 1995-06-30 1995-06-30
US08/497,357 1995-06-30
US59871596A 1996-02-08 1996-02-08
US08/598,715 1996-02-08

Publications (1)

Publication Number Publication Date
CA2225666A1 true CA2225666A1 (fr) 1997-01-23

Family

ID=27052471

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002225666A Abandoned CA2225666A1 (fr) 1995-06-30 1996-06-28 Utilisation de composes se liant specifiquement au domaine stat 5 sh2 pour augmenter l'erythropoiese

Country Status (5)

Country Link
EP (1) EP0835104A4 (fr)
JP (1) JPH10512585A (fr)
AU (1) AU6405596A (fr)
CA (1) CA2225666A1 (fr)
WO (1) WO1997002024A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0728482A3 (fr) * 1995-02-10 1999-10-20 Smithkline Beecham Corporation Emploi de composés HCP spécifiques pour augmenter l'érythropoiese
DE19929787A1 (de) * 1999-06-29 2001-01-04 Bayer Ag Neue 4-(2-Oxodihydrooxadiazinylphenyl)amide und ihre Verwendung
US7157487B2 (en) * 2000-12-28 2007-01-02 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
AU2004224191A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
JP4676884B2 (ja) 2003-07-24 2011-04-27 第一三共株式会社 シクロヘキサンカルボン酸類
CN1934092A (zh) 2004-03-23 2007-03-21 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
AU2006298853A1 (en) 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag NNRT inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4482571A (en) * 1982-06-21 1984-11-13 University Of Pittsburgh Sickle cell anemia treatment and compound
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
US4987121A (en) * 1988-05-27 1991-01-22 Center For Innovative Technology Erythropoietic factor
CA2054602C (fr) * 1991-10-31 2003-04-22 Anthony Pawson Methode de dosage d'une substance influant sur un systeme de regulation d'un ligand phosphoryle-sh2
WO1994007913A1 (fr) * 1992-09-25 1994-04-14 Warner-Lambert Company Antagonistes peptidiques de la fixation du sh2 et leurs usages therapeutiques
US5366996A (en) * 1992-12-07 1994-11-22 Elford Howard L Method of treating hemoglobinopathies
US5580979A (en) * 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
EP0728482A3 (fr) * 1995-02-10 1999-10-20 Smithkline Beecham Corporation Emploi de composés HCP spécifiques pour augmenter l'érythropoiese

Also Published As

Publication number Publication date
JPH10512585A (ja) 1998-12-02
AU6405596A (en) 1997-02-05
EP0835104A1 (fr) 1998-04-15
EP0835104A4 (fr) 1999-10-20
WO1997002024A1 (fr) 1997-01-23

Similar Documents

Publication Publication Date Title
AU2009243421B2 (en) Inhibitors of IAP
WO2020257412A1 (fr) Polythérapie avec des protéines chimériques ou des complexes protéiques chimériques ciblant cd13
CA2169136A1 (fr) Utilisation de composes specifique au domaine src sh2 pour traiter la resorption osseuse
KR20140101319A (ko) 인간 페리틴 유래 융합폴리펩티드
EP2841448A1 (fr) Peptides agonistes de par4
CA2225668A1 (fr) Utilisation de composes specifiques du domaine stat 6 sh2 pour le traitement des reactions allergiques
KR20060017865A (ko) 환상 3급 아민 화합물
CA2225666A1 (fr) Utilisation de composes se liant specifiquement au domaine stat 5 sh2 pour augmenter l'erythropoiese
CA2169132A1 (fr) Utilisation de composes specifiques au domaine hcp sh2 pour ameliorer l'erythropoiese
CA2212645A1 (fr) Utilisation de composes specifiques comportant lck sh2 pour le traitement de maladies auto-immunes et du rejet d'allogreffes
US7157552B2 (en) Mutant trichosanthin
US9512106B2 (en) Smoothened modulators and methods of use thereof
AU2011236020B2 (en) Inhibitors of IAP
US20030096760A1 (en) Method of antagonizing the human SRC SH2 domain
US10568886B2 (en) Targeting Cyb5R3
Yang Synthesis of 2, 4, 6-Substituted Pyrrolo [2, 3-d] pyrimidines as Potential Anticancer Agents
EP1007076A1 (fr) Procede permettant d'antagoniser le domaine humain src sh2

Legal Events

Date Code Title Description
FZDE Dead